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1. ABSTRACT
Thyroid cancer represents the most frequent 
endocrine neoplasm and is epidemiologically linked to 
a growing incidence worldwide, which is only in part 
explained by the increased detection of small cancers 
in a preclinical stage. Understanding the molecular 
pathogenesis of well-differentiated thyroid cancers and 
poorly-differentiated thyroid cancers has prompted 
interest into the identification of crucial signaling 
pathways and molecular derangements related 
to genetic and epigenetic alterations. Increasing 
attention has been recently focused on inflammation 
and immunity as major culprit mechanisms involved 
in thyroid tumourigenesis, through the detection of 
activated immune cells, pro-inflammatory cytokines, as 
well as signal integrations between inflammatory and 
proliferative pathways within the thyroid tumour micro-
environment. In addition to playing important roles in 
tumour surveillance and rejection, the presence of 
tumour-associated macrophages and the activation 
of NF-κB signaling pathway are now reckoned as 
hallmarks and crucial mediator of inflammation-
induced growth and progression of thyroid cancer. 
Thorough understanding of this immunological link 
and identification of novel molecular targets could 
provide unprecedented opportunities for research and 
development of diagnostic, prognostic and treatment 
strategies for thyroid cancer.
2. INTRODUCTION
Thyroid cancer is the most frequent 
endocrine neoplasia and its incidence rates are on 
the rise (1). Thyroid cancers are usually follicular or 
para-follicular in their origin, and lesions developing 
from follicular cells include well differentiated thyroid 
cancers (DTC), poorly differentiated (PDTC) and 
anaplastic (ATC) thyroid carcinomas (2). DTCs, which 
encompass papillary cancers (PTC) and follicular 
cancers (FTC), usually show a good prognosis after 
surgery and radioiodine therapy, yet 5–10% of cases 
progress to radioiodine refractory-disease. On the 
other hand, PDTCs and ATCs are therapy-resistant 
and prognosis is unfavorable (3). Medullary thyroid 
carcinoma (MTC), which originates from the para-
follicular C-cells, is either sporadic or familial and, by 
the time of diagnosis, shows high rate of lymph node 
metastases, which can elude detection pre-operatively 
or even intra-operatively (4).
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The role of inflammation in DTCs has been 
the focus of several studies published in the last 10 
years, which have demonstrated positive associations 
between chronic inflammation and increased risk of 
developing DTC, suggesting that the inflammatory 
microenvironment is an essential component of cellular 
transformation and tumour progression (5-8). In 
support of this inference, there has been demonstration 
that local activities engaged in thyroid tumourigenesis 
and thyroid cancer progression are positively 
influenced by two major inflammatory components: 
inflammatory cells along with their humoral mediators 
presenting within the cancer site, and activation of 
oncoprotein-mediated signalling present in epithelial 
cancer cells. Inflammatory cells and mediators enrich 
the tumour stroma and partake in several processes 
such as tissue remodelling, tissue repair and neo-
angiogenesis (9). Cancer stroma englobes both 
inflammatory cells engaged in antitumour effects and 
activated immune cells capable of pro-tumour immune 
responses, and the balance of antitumour/protumour 
immune responses culminates in the regulation of 
cancer suppression vs cancer progression (7,10). 
Cancer stroma thus plays a dominant role in the 
development and progression of DTCs (11-13), as well 
as it shows a potential role in MTC and PDTCs (5,14). 
The aim of this article is to provide an overview on the 
relationship between inflammation and thyroid cancer 
in relation to the immune mechanisms regulating 
thyroid cancer progression. To this purpose, our at-a-
glance description will mainly focus on DTCs, where 
essential evidences related to different histotypes and 
relative clinical aspects will be collectively described, 
whereas information resumed in MTC and ATC will be 
presented separately.
3. INFLAMMATION AND DTCs
In general, two pathways have been proposed 
to explain the link between inflammation and DTCs 
(15): the extrinsic (microenvironment-driven) and the 
intrinsic (oncogene-driven) pathways. 
3.1. Extrinsic pathway
3.1.1. Tumour-infiltrating inflammation
The extrinsic pathway is triggered by tumour-
infiltrating inflammation that includes leukocyte 
infiltration, tumour-associated macrophages (TAM), 
cytokines, chemokines and vascular endothelial 
growth factor (VEGF) (16). In PTC, TAM and immature 
dendritic cells accumulate both in tumour stroma and at 
the invasive front of the tumor, and the strength of their 
infiltrate positively correlates with capsular invasion, 
extra-thyroidal extension and aggressive behaviour of 
the tumour (17).
According to a classical view, tumours 
are encircled by extracellular matrix (ECM) with its 
structural and specialized proteins, as well as by 
stromal cells, which comprises cancer-associated 
fibroblasts (CAFs), innate and adaptive immune 
cells, specialized mesenchymal cells, endothelial 
cells and pericytes. CAFs impact cancer progression 
by a number of mechanisms, such as remodelling 
of the ECM, induction of angiogenesis, recruitment 
of inflammatory cells, and by redirecting cancer cell 
proliferation via secretion of growth factors, immune 
suppressive cytokines, and mesenchymal-epithelial 
cell interactions (18). Cancer stroma contributes to 
create the so-called tumour microenvironment (TME), 
which enfolds a significant inflammatory cell infiltrate 
capable of acting pleiotropically (19). While some cells 
are engaged in antitumour effects (i.e., dendritic cells, 
tumour infiltrating lymphocytes, M1 macrophages), 
others instigate a pro-tumour immune response (i.e., 
neutrophils, mast cells, NK cells, tumour infiltrating 
lymphocytes, M2 macrophages), such that the (un)
balance of antitumour/protumour immune responses 
intervenes to regulate cancer suppression vs cancer 
progression (7,10). Per se, TME acts as a reservoir of 
protumourigenic and proangiogenic cytokines, which 
are either produced by tumour cells, CAFs, innate or 
adaptive immune cells. The resulting inflammatory 
microenvironment is associated with the production of 
reactive oxygen species and oxidative stress initiated 
by the transcription of NF-kB, and perpetuated by 
activation of the MAPK pathway (19). Several lines of 
evidence state that TAMs promote cancer cell survival, 
proliferation, metastases, angiogenesis and immune 
suppression (20). Likely, the impact of TAMs on tumour 
progression depends on their specific reprogramming 
within the tumour. This process is influenced by factors 
related to local microenvironment such as hypoxia, 
locally released mediators (i.e. cytokines, growth 
factors), as well as metabolic products either released 
by cancer cells or other immune and stroma-related 
cells (21). Although pathways and mechanisms 
involved in TAMs reprogramming are not completely 
understood, activation of the AKT/mTOR pathway 
has been hypothesized to influence the inflammatory 
phenotype of DTC-associated macrophages (22).
Furthermore, Melillo et al (6) demonstrated 
the existence of a complex relationship between mast 
cells and thyroid cancer cells. In PTC, an increased 
density of mast cells was observed with respect 
to normal tissues, and this process is seemingly 
associated with a worse prognosis (6). In vitro, PTC 
cells recruited mast cells through tumour-derived 
VEGF-A; in turn, mast cells acted via histamine and 
chemokines (ex. CXCL-1, CXCL10) to induce cancer 
cell proliferation, survival and migration, by means of 
autocrine and a paracrine loops (6). Also TAMs and 
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mast cells have been experimentally and clinically 
shown to promote the progression of PTC (23).
3.1.2. Obesity-dependent inflammation
Obesity enhances the risk of at least 13 different 
cancers, and is a risk factor for tumour recurrence after 
curative surgery, poor survival, non-cancer-related as 
well as cancer-related mortality (24,25). Epidemiological 
linkage between excess body weight and thyroid cancers 
has been highlighted in cross-sectional studies (26,27) 
and confirmed in meta-analyses of cross-sectional (28) 
and prospective studies (26,27,29). In a pooled scrutiny 
of five U.S prospective studies, BMI was associated 
with thyroid cancer risk in both men and women, 
independent of tumour histology (30). Several lines of 
evidence suggest a potential role for adipose tissue 
(AT) accumulation in regulating TME pathophysiology, 
supported by associations found between obesity-
dependent inflammation and cancer (31). As such, there 
is demonstration that hypoxia, chronic inflammation and 
oxidative stress, which are typical of obese subjects, 
could favour the development of a subgroup of DTCs 
characterized by resistance to both 131I treatment and 
chemotherapy (31-33). The relevance of AT biology in 
thyroid tumourigenesis is mainly related to its ability 
to intervene both as a reservoir and regulator of key 
elements of the immune system, which involve production 
of immunomodulatory molecules and expression of their 
receptors within the AT (34,35).
It is known that AT englobes different cell 
populations, e.g. preadipocytes, mature adipocytes as 
well as immune and stromal cells. Pre-adipocytes have 
functional characteristics and transcriptional patterns of 
multipotent cells that are similar to immune cells, and 
can transdifferentiate into macrophages both in vitro 
and in vivo (36,37). Mature adipocytes share the ability 
to secrete cytokines acting as pro- or anti-inflammatory 
factors related to AT accumulation. Immune cells 
englobed in AT include pro-inflammatory T lymphocytes 
(predominantly CD8+), which contribute to local 
inflammatory cell activation by attracting macrophages, 
which perpetuate the inflammatory response within 
the AT (38,39). Both M1 and M2 macrophages can 
be found in AT (40). While resident M2 macrophages 
play dominant roles in AT physiology and are able 
to produce anti-inflammatory cytokines, M1-like 
macrophages are recruited and clustered within the AT 
as crown-like structures (CLSs) and, upon stimulation 
by IFNγ or lipopolysaccharide, they are able to produce 
pro-inflammatory cytokines, thus contributing to 
inflammatory pathways relating to insulin resistance 
(41-44). This suggests that M1 and M2 play opposed 
roles in AT pathophysiology as compared to that seen in 
DTCs. AT hypoxia may promote the M2 to M1 switching 
(45), and these macrophages are responsible for AT 
expression of TNFα, as well as production of discrete 
amounts of iNOS and IL6 (43). TNFα is a cytokine 
capable of anti-proliferative actions in a human PTC 
line, through a receptor-mediated mechanism (46). 
Nevertheless, the high TNFα exposure related to 
obesity seems to induce a state of TNFα resistance, 
which ultimately facilitates thyroid tumour progression 
(31,46) and metastatic diffusion (47). IL-6 is a cytokine 
involved in tumourigenesis (48), but its role in thyroid 
cancer is still confusing. Although results linking directly 
thyroid cancer to IL-6 are scant (49,50), IL-6 could be 
important for the inflammation microenvironment in 
thyroid carcinogenesis, influencing DTC development 
and progression (7,48). Recently, Kobawala et al 
(51) demonstrated that IL-6 mRNA expression is 
higher in the primary tumour tissues of PTC patients 
as compared to the corresponding adjacent normal 
tissues, and that serum IL-6 correlates with larger 
tumour size, presence of distant metastasis, extra-
thyroidal extension and poor overall survival.
The obesity-related adipocytokine network 
could also play a role in relation to the development 
of thyroid cancer (7,31,33,52). Mature adipocytes 
produce leptin, which is involved in activation of 
monocytes and macrophages, stimulation of VEGF and 
angiogenesis, and suppression of anti-inflammatory 
cytokines. Leptin promotes cell migration of PTC, while 
inhibiting the migration of follicular cells (53). Studies 
in vitro demonstrated that leptin is able to stimulate 
a more aggressive PTC phenotype by activating the 
PI3K/AKT pathway (54). Moreover, leptin promotes the 
de-differentiation of thyroid cancer cells via the JAK2/
STAT3 signalling pathway (55). Recently, Fan et al 
(56) demonstrated that leptin had negative prognostic 
significance in PTC, whereas it may play a protective 
role in FTC.
On the contrary, adiponectin, an adipocytokine 
capable of exerting strong anti-inflammatory, 
proapoptotic and antiproliferative effects, appears to be 
inversely correlated with occurrence and proliferation 
of DTCs, hence suggesting its protective effect against 
thyroid tumourigenesis (57). Accordingly, Cheng et 
al (58) found that, when tissues were negative for 
adiponectin receptors, tumours were significantly 
associated with extrathyroidal invasion, multicentricity, 
and higher TNM stage, demonstrating that the 
expression of adiponectin receptors could associate 
with a better prognosis. Further potential links between 
obesity-related inflammation and DTC are represented 
by ghrelin and obestatin. In particular, a recent review 
reported that lower levels of ghrelin would favour 
thyroid cell proliferation, whereas supra-physiological 
levels would have an inhibitory effect (33). 
Obesity-induced inflammation involves other 
inflammatory components that could contribute to 
tumourigenesis. These components include matrix 
metalloproteinases (MMPs), which are associated with 
cancer-cell invasion and metastasis (59-62).
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Finally, the possible association between 
obesity and autoimmune thyroid diseases might 
also play a role because of the link between chronic 
autoimmune thyroiditis and thyroid cancer (63).
4. INTRINSIC PATHWAY
4.1. Genetic alterations
The intrinsic pathway is driven by genetic 
alterations most frequently found in association with 
DTC, such as RET/PTC rearrangement and BRAF 
point mutation. Up to 70% of PTCs express non-
overlapping mutations of RET, TRKA, RAS and BRAF 
genes, which encode the transcription of components of 
the mitogen-activated protein kinase (MAPK) cascade 
(5). Both point-mutations and genetic rearrangements 
can promote the constitutive activation of the tyrosine 
kinase activity of RET in the absence of ligands. 
Activation of RET by physiological ligands or by 
oncogenic conversion results in the phosphorylation of 
intracellular tyrosine residues, which serve as docking 
sites for the recruitment of signalling adapters (64-66). 
Local activities engaged in thyroid 
tumourigenesis and thyroid cancer progression are 
positively influenced by the activation of oncoprotein-
mediated signalling present in epithelial cancer 
cells. Studies investigating the role of the RET/
PTC3 oncoprotein in the recruitment of immune cell 
populations into the tumour site (67-70) showed 
that the transplantation of RET/PTC3-expressing 
thyrocytes activates an inflammatory transcriptional 
program both in vitro and in vivo, and PTC-like lesions 
in mice were characterized by a leukocytic infiltrate 
mainly constituted by macrophages, with parallel 
increase in cytokine production within the tumour 
(71). Main humoral components of this program 
include mediators responsible for different pro-tumour 
effects, such as growth factors implicated in leucocyte 
recruitment and survival (G-CSF; GM-CSF, M-CSF), 
chemokines (CCL2, CXCL12), chemokines receptors 
(i.e. CXCR4) implicated in monocyte recruitment, 
angiogenesis and tumour-cell homing to lymph nodes, 
IL-8, L-selectin and proteases responsible for tumour 
invasion and dissemination. RET/PTC3-positive 
thyroid cancers were also found to induce recruitment 
of CD11b+, Gr1+ cells capable of mediating tumour 
escape from the immune surveillance (72). Oppositely, 
the expression of the RET/PTC3 isoform in a rat thyroid 
cell line (PC Cl3) was demonstrated to increase NF-kB 
DNA-binding activity with consequent increase in the 
pro-inflammatory cytokine secretion (73).
NF-kB is a transcription factors laying at 
the intersection between the intrinsic and extrinsic 
proinflammatory pathways related to tumourigenesis 
(15). High constitutive expression of NF-κB is a primary 
feature of cancer cells but not normal cells, indicating 
a crucial role for NF-κB in regulating tumourigenesis 
(74). NF-κB comprises a family of transcription factors 
involved in transcription of different genes controlling 
apoptosis, immune response and inflammation, as well 
as cancer development and progression. Activation 
of NF-κB results from different signalling pathways 
triggered by cytokines, growth factors, and tyrosine 
kinases (75,76). NF-κB is also recognized to play a 
major role in the initiation and progression of thyroid 
carcinoma (77,78). In thyroid cancer cells, oncogenic 
proteins RET/PTC, RAS and BRAF can induce NF-κB 
activation in PTC, FTC, and MTC, while constitutively 
de-regulated NF-κB activity has been found in ATC 
(75). In a subset of PTCs associated with unfavourable 
outcome, it has been shown that NF-κB-mediated anti-
apoptotic effects are enhanced by over-activation of 
Ras-related C3 botulinum toxin substrate 1 (RAC-1b), 
a hyperactive variant of the RAS superfamily of small 
GTP-binding proteins (79).
4.2. The immune network
Conflicting reports deal with the association 
between the prognosis of PTC and the degree of 
lymphocytic infiltration surrounding and/or inside 
the tumour (80-83). Several studies suggest that the 
immune response might be important in preventing 
metastases and recurrence of thyroid cancer, 
improving disease-free survival (63,84,85). On the 
contrary, other studies showed that patients with 
tumour-associated lymphocytes exhibited higher 
disease stage and increased incidence of invasion and 
lymph node metastases compared to patients without 
lymphocytes, or with background thyroiditis (13,86,87).
Moreover, recent studies (88,89) showed 
important clinical implication of autoimmunity on tumour 
behaviour; in particular, Stassi et al (89) demonstrated 
that IL-4 and IL-10 activation induce thyroid cancer 
cells resistance to chemoterapeutic agents.
Autoimmunity stimulates the production 
of higher levels of proinflammatory cytokines with 
growth factor activity (IL-17, IFN-γ and TNF-α) and the 
angiogenesis enhanced by TNF-α and VEGF (84,90-
94). Moreover, high-mobility group box 1 protein 
(HMGB1), a late inflammatory cytokine that signals 
danger to the immune system, and nitric oxide can 
be detected both in thyroiditis and PTC patients, and 
have been found to promote matrix remodelling, inhibit 
immune response and suppress cell cycle regulators, 
thus increasing the risk of PTC proliferation (95). 
Reactive oxygen species (ROS) also contribute to DNA 
damage and promote the epithelial-to-mesenchymal 
transition (62). Two hypotheses may explain the 
association between autoimmune thyroiditis and 
differentiated thyroid cancer. In both cases, RET/
PTC rearrangement can contribute to modulate 
the autoimmune response (84,94,95). In fact, RET/
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PTC rearrangement is considered specific for PTC 
but can also occur in non-neoplastic conditions like 
Hashimoto’s thyroiditis (97). In vivo studies showed 
that RET/PTC rearrangement is more represented in 
PTC when it is associated with thyroiditis, whereas 
BRAFV600E are more often observed in PTC alone 
(67,88). According to this hypothesis, free radicals 
production, cytokine secretion, cellular proliferation as 
well as other phenomena related to local inflammation 
could predispose to RET/PTC rearrangement in 
follicular cells and favour tumorigenesis (98). The 
second hypothesis is supported by the observation 
that RET/PTC3 rearrangement expresses high levels 
of proinflammatory cytokines and proteins involved in 
the immune response (6,70,73,99). Likewise, there 
is evidence that RET/PTC1 rearrangement is able to 
induce the expression of genes involved in inflammation 
and tumour invasion, including chemokines, chemokine 
receptors, cytokines, adhesion molecules and matrix-
degrading enzymes (69). Other gene alterations have 
been proposed to explain the association between 
thyroid cancer and autoimmune thyroiditis. For 
example, p63 protein is commonly expressed in both 
PTC and Hashimoto’s thyroiditis (100), suggesting p63 
expression as a potential link between these conditions 
(101). Moreover, the increased expression of p-Akt, 
Akt1, and Akt2 in thyroid cancer and autoimmune 
thyroiditis suggests PI3K/Akt pathway to be involved in 
both disorders (102).
Other molecules involved in the immune 
network relating to DTCs include chemokines, which 
contribute to the development and progression of 
cancer (103,104) and tumour metastasis (105,106). 
Chemokines are a family of about 50 chemotactic 
proteins (8–10 kDa) classified into four highly 
conserved groups—CXC, CC, C, and CX3C—
based on the position of their first two cysteines 
adjacent to the amino-terminal region (107,108). 
These molecules can stimulate cell migration during 
inflammation, as well as the homeostatic transport of 
hematopoietic stem cells, lymphocytes, and dendritic 
cells (109,110). The activity of chemokines is mediated 
by receptors, which promote the signaling leading to 
the transcription of genes required for cell motility, 
invasion, interaction with the extracellular matrix, 
and cell survival (107,111,112). The main chemokine 
receptors expressed in thyroid cancer include CXCR4 
and CCR7 (113,114). CXCR4 has been studied due 
to its association with the presence of extranodal 
extension and thus a more aggressive behavior and 
negative prognosis (115). CCR7 is also expressed 
in thyroid carcinoma cell lines (TPC-1) and thyroid 
cancer tissues (113,114), and is thought to contribute 
to tissue invasion and cellular proliferation (113). CCR3 
is another receptor associated with development, 
progression, and aggressiveness of several types of 
cancer, included DTC (116,117).
Finally, recent analysis has focused on 
immune checkpoints as a prognostic and therapeutic 
tool for DTCs. In a study assessing immunostaining 
and mRNA levels of programmed death-ligand 1 (PD-
L1), a macrophage-related cell surface glycoprotein 
regulating local inflammatory responses, more intense 
expression was observed in samples from DTCs 
than those from benign tumours, and increasing 
PD-L1 mRNA expression was demonstrated in 
more advanced tumour stages (118). Similarly, an 
increased expression of PD-L1 has been observed in 
advanced DTCs and ATCs, both at the cellular level 
and on tumour-associated lymphocytes (119). While 
these findings await confirmation in Tregs, TAMs, 
and immature dendritic cells, it appears feasible that 
studies focusing on immune checkpoint inhibitors 
in DTCs could lead the way to test new therapeutic 
strategies (120).
Immunotherapies show promise for providing 
oncologists with a novel array of therapeutic tools in the 
near future (121). Cancer immunotherapies have been 
approved in recent years, including preventive and 
therapeutic cancer vaccines (122), the first immune 
checkpoint inhibitors (123,124), a bi-specific T-cell 
engager, and an oncolytic virus (125). Experience 
with ipilimumab (CTLA-4 antagonist), nivolumab and 
pembrolizumab (PD-1 antagonists), and atezolizumab 
(PD-L1 antagonist) has shown a marked impact on 
overall survival in cancer patients. Immune checkpoint 
inhibitors that target the PD-1 pathway generated the 
greatest interest, with response rates across tumour 
types that averaged 20-30% (126). Intuitively, the 
effectiveness of the combination of CTLA-4 and 
PD-1/PD-L1 blockade on overall survival (OS) will be 
proved to be higher than single therapy (such as in 
other cancers) (127). However, the use of immune 
checkpoint inhibitors in aggressive thyroid cancer 
has not been extensively investigated yet, and further 
studies in a large number of patients are warranted.
5. INFLAMMATION AND MTC
Data regarding the potential link between 
MTC and cancer-related inflammation (CRI) originate 
from few in vitro studies. In MTC, the intrinsic pathway, 
which is driven by genetic alterations associated with 
thyroid carcinogenesis, seems to play a major role in 
this link. Germline point mutations of proto-oncogene 
RET are known to be responsible for almost all familial 
MTC in multiple endocrine neoplasia (MEN) type 2A 
and 2B, and familial medullary thyroid carcinoma 
(FMTC), while somatic point mutations are found in up 
to 50% of patients with sporadic MTC (128).
RET encodes for the tyrosine kinase receptor 
of growth factors belonging to the Glial cell-Derived 
Neurotrophic Factor (GDNF) family, the stimulation 
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of which activates a variety of signalling pathways, 
such as the RAS/ERK, the PI3-K/AKT and the MAPK 
pathways, which are involved in cell survival and 
differentiation. Gain-of-function mutations of RET 
cause a constitutive activation of the tyrosine kinase 
activity of the receptor in the absence of ligands, 
leading to tumour development and progression (129).
In vitro studies (129) demonstrated that 
GDNF stimulation induced high level of interleukin-8 
(IL-8) production in the TT medullary thyroid 
carcinoma cell lines. IL-8 is a pro-inflammatory, 
mitogenic and proangiogenic chemokine that is known 
to be involved directly in tumour growth, cell migration, 
and angiogenesis in an autocrine or paracrine way, 
or indirectly by attracting infiltration cells, including 
neutrophils and macrophages; therefore, its 
expression in tumour cells may affect their biological 
properties such as invasion and metastatic ability 
(16,129). Transcription of IL-8 is known to depend on 
activation of Nuclear factor interleukin-6 (NF-IL-6) and 
NF-kB (129,130).
Two reports have associated RET-mediated 
carcinogenesis with NF-κB activation, so far (76,130). 
Ludwig et al. (131) found that NF-κB was strongly 
expressed in tissue specimens from parafollicular 
C-cell carcinomas, and in vitro data suggested that 
NF-κB-dependent transcription plays an essential role 
in the development of MTC induced by both oncogenic 
RET isoforms, i.e. those harboring the mutations 
C634R or M918T, responsible for MEN 2A and MEN 2B, 
respectively. Gallel et al. (76) also demonstrated that 
the expression of mutated RET induces an increase 
in NF-κB DNA-binding activity and a consequent 
increase in pro-inflammatory cytokine secretion.
RET-mediated transformation would be 
dependent on NF-κB delivered anti-apoptotic and 
mitogenic signals. Since most part of pro-inflammatory 
molecules are under NF-κB transcriptional control, it 
has been hypothesized that NF-κB could be involved in 
the regulation of pro-inflammatory program of thyroid 
cells, and this event would contribute to the onset of 
thyroid cancer (75).
6. INFLAMMATION AND ATC  
There are studies suggesting that inflammation 
could also be a key factor involved in the development 
of ATC, one of the most lethal human malignancies. 
Many characteristics of the inflammatory status leading 
to enhanced tumour growth, invasion, angiogenesis, 
and metastasis, are similar between ATC and PDTC, 
that is the bridge between DTC and ATC.
Compared to DTC and normal thyroid, ATC and 
PDTC show an increased amount of TAMs accounting 
for about more than 50% of immune cells infiltrating 
ATC. Infiltrate of TAMs is higher in PDTCs and ATCs 
than in PTCs and FTCs, and positively correlated with 
the poor prognosis of PDTCs (17). TAMs usually form 
a “microglia-like” structure that is in close contact with 
cancer cells, and their inter-connection and density 
correlate with invasive features and worse prognosis of 
the tumour (21,132,133), as confirmed by the evidence 
that TAMs infiltrate promoted the invasiveness of ATC 
cell lines in vitro through production of CXCL8/IL-8 
(21). In contrast to TAMs, infiltration of lymphocytes 
and dendritic cells, which are involved in antitumour 
response (7,10), is reduced or absent in ATC (134). In 
ATC cell lines, CXCL8/IL-8 plays a central role in cell 
proliferation both during unstimulated conditions and 
under the effect of pro-inflammatory stimuli, such as 
IL-1 and TNF-α (21,134). Recruitment of neutrophils 
within the thyroid gland, a crucial metastasis-
promoting factor, is dependent on the amount of 
CXCL8 produced by the tumour cells when exposed 
to TNF-α (135,136). Moreover, there is evidence 
that reduced expression of CXCL8/IL-8 and MCP-1/
CCL2 pathways by the oncolytic adenovirus dl922-
947 is able to impair angiogenesis and macrophage 
infiltration, and to promote ATC cell death in vitro as 
well as tumour regression in vivo (137). In a recent 
study on a xenograft mouse model, it has been shown 
that several cytokines expressed in ATC cell lines and 
tumour tissues, such as IL-8, TGF-α, and TNF-α, can 
be down-regulated by suppressing the ubiquitin-like 
containing PHD and RING finger domains 1 (UHRF1) 
(138). The protein binds to specific DNA sequences, 
and recruits a histone deacetylase to regulate gene 
expression. This UHRF1-mediated effect was found to 
be associated with inhibited proliferation of ATC, both 
in vitro and in vivo (138).
Moreover, inflammatory conditions relating 
to production of INF-γ and TNF-α can promote the 
autocrine production of IL4, IL10, CXCL1/GRO-α, 
CXCL10/IP-10 in primary human ATC cells (as well 
as in DTCs), and potentially contribute to up-regulate 
anti-apoptotic pathways and chemo-resistance 
(89,139). Also mast cells are present in ATC, and 
their infiltrate is directly correlated with tumour 
invasiveness through production of soluble factors 
involved in epithelial-to-mesenchymal transition, 
with CXCL8/IL-8 acting, again, as main effector 
of this mechanism (133). Furthermore, mast cell-
derived CXCL1/GRO-α and CXCL10/IP10 production 
increased ATC proliferation through the engagement 
of CXCR2 and CXCR3 expressed on thyroid cells 
(6). Interestingly, the activation of the CXCL10-
CXCR3 axis was also induced by NK cell migration 
in ATC cell lines. Prostaglandin-E2 was identified as 
the main responsible for the ATC-mediated NK cell 
suppression (140). 
At odds with results obtained in DTCs, there is 
no evidence of a connection between the oncogenetic 
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background of ATCs and inflammation. Likewise, no 
associations have been found between Hashimoto’s 
thyroiditis or thyroid lymphoma and ATC incidence. 
Finally, it is worth mentioning that 
observational studies in humans have investigated 
different inflammatory biomarkers as a tool to assess 
aggressiveness of different thyroid cancers subtypes. 
The neutrophil-to-lymphocyte ratio, a simple surrogate 
index of the systemic inflammatory response, was 
shown to be a prognostic factor in some types of 
cancers. In a cohort of 3,870 patients affected by 
benign or malignant thyroid diseases, the neutrophil-
to-lymphocyte ratio differed between tumour cancer 
subtypes and was 3.8.-fold higher in ATC than in PDTC 
or PTC patients (141). Moreover, also eosinophilia 
refractory to steroids has been recently reported in 
an ATC patient (142). Finally, serum levels of IL10 
and C-reactive protein in ATC patients were directly 
correlated with higher peripheral blood myeloid cells 
(MDSSCs), which are known to be immunosuppressive 
and cancer promoting (143).
7. CONCLUSIONS
The link between inflammation and thyroid 
cancer involves multiple components of the immune 
system, ECM, stroma, and AT (5), with pro-tumoural 
activity of inflammation being is opposed to anti-
inflammatory effects favoring protection against cancer 
progression (7,10).
Within the tumour microenvironment, 
inflammatory cells, belonging both to innate 
(macrophages) and adaptive (lymphocytes) immune 
responses, are interconnected with fibroblasts, 
endothelial cells, adipocytes, and ECM through 
cytokines, chemokines and adipocytokines (16). Under 
the influence of transcriptional regulators, such as 
NF-kB, PI3K-AKT and MAPK, oncogenes connected 
to the different subtypes of thyroid carcinomas 
promote their furthermost proliferative effect on the 
tumor microenvironment. 
As recently reviewed by Antonelly and 
coworkers, cancer-related inflammation could 
represent an important target for innovative diagnostic 
and therapeutic strategies in thyroid cancer (127). The 
molecular patterns of cytokines and chemokines are 
key orchestrators and could explain the involvement 
of the immune system in tumour progression. In fact, 
anticancer immunotherapy, in particular the immune 
checkpoint inhibitors, act by promoting lymphocyte 
activation in order to destroy cancer cells and 
counteract immune-suppressive signals produced 
by cancer cells (118). By doing so, they also activate 
immune memory, leading to a sustained anti-tumour 
response (118). 
Further information on the inflammatory 
microenvironment may help to explain tumour 
aggressive behaviour and identify potential new 
targets of therapy.
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